Neuphoria Therapeutics’ (NEUP) Neutral Rating Reaffirmed at HC Wainwright

Neuphoria Therapeutics (NASDAQ:NEUP)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a report released on Friday,Benzinga reports.

A number of other equities research analysts have also issued reports on NEUP. Zacks Research raised shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Neuphoria Therapeutics currently has a consensus rating of “Hold” and an average target price of $21.00.

Neuphoria Therapeutics Price Performance

Shares of NEUP traded down $0.33 during mid-day trading on Friday, reaching $4.76. The stock had a trading volume of 50,005 shares, compared to its average volume of 44,659. Neuphoria Therapeutics has a 52-week low of $3.64 and a 52-week high of $21.40. The business’s fifty day moving average is $4.72 and its 200 day moving average is $4.38. The firm has a market cap of $25.66 million, a price-to-earnings ratio of -1.09 and a beta of 0.72.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. As a group, sell-side analysts anticipate that Neuphoria Therapeutics will post -4.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of NEUP. AdvisorShares Investments LLC lifted its position in Neuphoria Therapeutics by 129.1% in the fourth quarter. AdvisorShares Investments LLC now owns 134,194 shares of the company’s stock valued at $521,000 after buying an additional 75,631 shares during the last quarter. Ikarian Capital LLC acquired a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth about $184,000. ADAR1 Capital Management LLC acquired a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth about $116,000. Diadema Partners LP lifted its position in shares of Neuphoria Therapeutics by 133.1% during the fourth quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock worth $194,000 after purchasing an additional 28,548 shares in the last quarter. Finally, FNY Investment Advisers LLC acquired a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth about $102,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.